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Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed mainly
in patients with high-risk or advanced hematologic malignancies and congenital or acquired aplastic
anemias. In the context of the significant risk of graft failure after allo-HSCT from alternative
donors and the risk of relapse in recipients transplanted for malignancy, the precise monitoring of
posttransplant hematopoietic chimerism is of utmost interest. Useful molecular methods for
chimerism quantification after allogeneic transplantation, aimed at distinguishing precisely between
donor's and recipient's cells, are PCR-based analyses of polymorphic DNA markers. Such analyses
can be performed regardless of donor's and recipient's sex. Additionally, in patients after sex-
mismatched allo-HSCT, fluorescent in situ hybridization (FISH) can be applied.
Methods: We compared different techniques for analysis of posttransplant chimerism, namely
FISH and PCR-based molecular methods with automated detection of fluorescent products in an
ALFExpress DNA Sequencer (Pharmacia) or ABI 310 Genetic Analyzer (PE). We used Spearman
correlation test.
Results: We have found high correlation between results obtained from the PCR/ALF Express and
PCR/ABI 310 Genetic Analyzer. Lower, but still positive correlations were found between results
of FISH technique and results obtained using automated DNA sizing technology.
Conclusions: All the methods applied enable a rapid and accurate detection of post-HSCT
chimerism.
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Background
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is performed mainly in patients with high-risk or
advanced hematologic malignancies and aplastic ane-
mias, and for some of them it is the only curative treat-
ment. After allo-HSCT, incomplete engraftment and
appearance of recipient's hematopoietic cells can lead to a
coexistence of donor and host hematopoiesis – a situation
known as mixed chimerism. Complete recovery of hemat-
opoiesis of the donor origin is referred to as complete
chimerism.
Widely accepted molecular methods for analysis of chi-
merism after allo-HSCT, aimed at distinguishing precisely
between donor's and recipient's cells, are PCR-based anal-
yses of polymorphic DNA markers, such as variable
number of tandem repeats (VNTR) or short tandem
repeats (STR) [1]. Such analyses can be performed regard-
less of donor's and recipient's sex [2]. Additionally, in
patients after sex-mismatched allo-HSCT, fluorescent in
situ hybridization (FISH) can be applied. This technique is
based on identification of Y-chromosome-specific
sequences in the posttransplant sample examined. Vari-
ants of these techniques can be used for precise, quantita-
tive assessment of the amount of donor's cells in
recipient's peripheral blood and/or bone marrow after
transplantation, in the long run giving a picture of the
dynamics of changes in chimeric status within a hemat-
opoietic compartment. Chimerism also reflects response
to treatment [3], since it correlates with the risk of malig-
nancy relapse. Relapse is the most frequent cause of treat-
ment failure in recipients transplanted for hematologic
malignancies, but it is still controversial if patients with
mixed chimerism have an increased risk of developing
relapse or graft failure. Most probably only a progressive
mixed chimerism (a dynamic rise in the number of recip-
ient's cells over time) seems to reflect a relapse or rejec-
tion. Successful outcome has been associated with a state
of stable complete chimerism [4].
Here we report results of a comparison of different tech-
niques for analysis of posttransplant chimerism: fluores-
cent  in situ hybridization (FISH) and PCR-based
molecular methods with fluorescent products detected in
an ALF Express DNA Sequencer (Pharmacia) or ABI 310
Genetic Analyzer (PE).
Methods
Patients
Investigation of hematopoietic chimerism was performed
in ten children (eight girls, two boys) aged 6–16 years.
They were diagnosed with acute myelogenous leukemia
(n = 4), acute lymphoblastic leukemia (n = 2), chronic
myelogenous leukemia (n = 1), myelodysplastic syn-
drome (n = 1), or Fanconi Anemia (n = 2). All recipients
received hematopoietic stem cells from HLA-matched sib-
ling donors, and sex-mismatch between donor and recip-
ient was present in all cases. The material (peripheral
blood) for hematopoietic chimerism quantification was
collected in different periods after transplantation. In all
10 children reconstitution of hematopoiesis was
observed. Out of 8 children transplanted for hematologic
malignancies, 4 are well and alive, in complete continu-
ous remission (CCR), while in the other 4, leukemia
relapse occurred 4–23 months after transplantation.
DNA isolation
High-molecular-weight DNA was extracted from frozen
whole blood (approximately 5 ml) or bone marrow
(approximately 3–5 ml) by the standard treatment with
sodium dodecyl sulfate (SDS) and proteinase K, and the
salting-out method. DNA was isolated from the donors'
and patients' blood samples collected before and after
transplantation at various intervals in order to determine
the chimeric status.
Analysis of PCR products by an ABI 310 Genetic Analyzer
The PCR protocol optimized for the Qiagen polymerase
and the PE 9700 thermocycler was performed as described
previously [5]. For fragment analysis (after capillary elec-
trophoresis), an ABI 310 Genetic Analyzer (PE) was used
[5]. All analyses were performed in the University Chil-
dren's Hospital, Tuebingen.
Analysis of PCR products by an ALF Express DNA 
Sequencer
The PCR protocol optimized for the Thermal Controller
MJ Research (Watertown, MA) model PTC-100™ was
applied. PCR was performed in a volume of 10 µl; the PCR
reaction mixture contained: 2.5 pM of each forward and
reverse primer, 200 µl of each dNTP, 0.4 U Taq polymer-
ase (Qiagen, Chatsworth, CA), 1x PCR buffer (Qiagen,
Chatsworth, CA), and 40 ng of genomic DNA. Conditions
for PCR were as follows: 5 min at 94°C for the first dena-
turation; 26 cycles of amplification with a temperature
profile of 45 sec at 94°C, 1 min at 55°C, 1 min at 72°C;
with additional 5 min at 72°C in the last cycle. STR loci
were amplified with fluorescent PCR primers described
previously [6]. Primers for microsatellite markers were
labeled with Cy5 dye (TIB MOLBIOL). A 1.5-µl aliquot of
PCR reaction was resuspended in 7 µl of loading solution
(formamide, bromophenol blue) containing 100 bp and
300 bp internal markers. All samples, after denaturation
at 95°C for 5 min, were analyzed on 6% denaturing poly-
acrylamide gel with 7 M urea in the sequencer. A 50–500
sizer labeled with Cy5 dye was used as an external marker
(for calculation of allele sizes). Electrophoresis was car-
ried out in 0.6xTBE buffer at 1500 V/min. The helium-
neon laser was operated at a wavelength of approximately
700 nm and laser power value of 2.5 mW. Allele sizes andBMC Blood Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2326/5/1
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Table 1: Comparison of results using different DNA sizing technologies and FISH
No. UPN Sex F/M Diagnosis Material 
examined
HSCT 
date
Days after 
HSCT
PCR/ALF 
Express*
PCR/ ABI 310 
Genetic Analyser*
FISH with probes 
specific to X, Y 
chro-mosomes*
1. 67 F AML PB 04.09.1998 542 100% 100% 100% 
556 100% 100% 100%
574 100% 100% 100%
590 100% 100% 100%
639 100% 100% 100%
675 100% 100% 100%
697 100% 100% 100%
721 100% 100% 100%
750 100% 100% 100%
2. 102 M AML PB 12.10.2000 14 84% 86% 89%
19 49% 47% 51%
28 40% 40% 35%
35 47% 42% 12%
57 46% 35% 6%
3. 106 M FA PB 21.12.2000 7 100% 100% 92%
48 26% 27% 32%
91 13% 14% 9%
4. 87 F FA PB 27.12.1999 21 10% 28% ND
38 93% 94% ND
285 15% 18% ND
313 17% 19% ND
357 0% 0% ND
5. 45 F CML PB 15.11.1996 953 0% 0% ND
1030 0% 0% ND
1216 0% 0% ND
1284 0% 0% 0%
1374 0% 0% 0%
1459 0% 0% 0%
1492 0% 0% ND
6. 93 F AML PB 20.04.2000 28 0% 0% 0% 
158 0% 0% 0%
277 0% 0% 0%
7. 109 F MDS PB 26.01.2001 14 0% 0% 0%
21 0% 0% ND
34 0% 0% ND
42 0% 0% ND
8. 108 F ALL PB 19.01.2001 17 0% 0% ND
21 0% 0% ND
26 0% 0% 2%
39 0% 0% ND
52 0% 0% ND
60 0% 0% ND
9. 88 F AML PB 21.01.2000 29 0% 0% ND
87 0% 0% 0%
178 0% 0% ND
267 0% 0% ND
365 0% 0% 2%
10. 95 F ALL PB 16.06.2000 27 0% 0% ND
83 0% 0% ND
200 0% 0% ND
218 0% 0% 1%
ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; FA = Fanconi Anemia; FISH = 
fluorescent in situ hybridization; HSCT = hematopoietic stem cell transplantation; MDS = myelodysplastic syndrome; ND = no data; PB = peripheral 
blood; UPN = unique patient's number
* results expressed as % of recipient's cellsBMC Blood Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2326/5/1
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peak areas of fluorescent products were analyzed and cal-
culated with the use of Fragment Manager software (Phar-
macia). PCR and analysis of PCR products by the ALF
Express DNA Sequencer was performed at the Institute of
Human Genetics, Poznan.
FISH
The experiments were performed on interphase nuclei
obtained by standard short culturing of fresh whole blood
samples, with probes specific for chromosomes X (locus
DXZ1) and Y (locus DYZ1). The FISH procedure accord-
ing to Cytocell Ltd. was used [7]. The number of scored
nuclei was 250 to 550, with a median of 300. FISH exper-
iments were performed at the Institute of Human Genet-
ics, Poznan. Since the material for FISH analysis was not
collected in all designated periods after transplantation in
some patients, FISH experiments were not performed
then.
Quantification of chimerism
After electrophoresis in the ABI 310 Genetic Analyzer
(PE), all obtained data were analyzed by GeneScan 3.1
software and then transferred to Genotyper 2.5 software
[5]. All data obtained after electrophoresis of fluorescent
products in the ALFExpress DNA Sequencer were trans-
ferred to Fragment Manager™ software (Pharmacia). For
both, calculation of the amount of recipient's DNA was
performed using the formula:
% of recipient's DNA = (R1 + R2)/(D1+ D2 + R1 + R2) ×
100,
where: R1, R2 = peak areas of recipient's alleles; and D1,
D2 = peak areas of donor's alleles.
Only informative markers were used for the analysis. If
donor and recipient were heterozygous but shared one
allele, only the area of the non-shared alleles was consid-
ered for the analysis [8].
To make sure that quantification is accurate, we per-
formed serial dilution experiments, where standardized
mixed chimeric samples were created by mixing donor's
and pretransplant recipient's DNA in a range between 0
and 100 percent. The sensitivity strongly depends on the
size of alleles, the detection level was around 3–5% of
patient cells.
The results of chimerism detection by different methods
were compared by the Spearman correlation test.
Results
The results of chimerism quantification with the use of an
ALF Express DNA Sequencer, ABI 310 Genetic Analyzer,
and FISH are compared in Table 1. In three patients (no.
5, 6, 7) only donor's cells were detected in all post-HSCT
samples and in one patient (no. 1) only recipient's cells
were present in all samples examined. These results were
confirmed with the use of all three methods. Three other
patients (no. 2, 3, 4) exhibited mixed posttransplant chi-
merism according to PCR and/or FISH. In the last three
patients (no.8, 9, 10), complete chimerism was detected
by PCR and automated DNA sizing, but in some of their
samples, low numbers of recipients' cells were detected by
FISH.
Coefficients of Spearman rank correlation between results
of chimerism quantification by the three different meth-
ods are shown in Table 2. All coefficients were statistically
significant (p < 0.001). The correlation between PCR/ALF
Express and PCR/ABI 310 was stronger than between FISH
and both PCR methods.
Comparison of methods used
One of the advantages of application of automated DNA
sizing techniques for detection of posttransplant chimer-
ism is that the use of radioactivity is not necessary. It is
arelatively simple and rapid method, consisting of two
steps: polymerase chain reaction with fluorescent primers
and automated detection of fluorescently labeled PCR
products, separated by electrophoresis. The analysis of flu-
orescently labeled PCR products provides better accuracy
and precision of measurement than traditional electro-
phoretic methods. The most time-consuming step, which
might prolong the examination process, is the search for
informative markers.
Analysis of the chimerism status by amplification of STR
loci can be performed regardless of donor's and recipient's
sex. The most advantageous is the high sensitivity of the
detection system used, so that only small amounts of
DNA are needed.
Fragment analysis in the ABI 310 Genetic Analyzer (PE) is
performed after capillary electrophoresis. The examina-
tion of one sample requires about 6 hrs; 144 samples can
be analyzed per day if three colors are simultaneously ana-
lyzed [5]. The advantage of this method is that thanks to
Table 2: Coefficients of Spearman rank correlation between 
results of chimerism quantification by different methods (all 
coefficients significant, P < 0.001).
PCR/ABI 310 
Genetic Analyzer
FISH
PCR/ALF Express 0.987 0.801
PCR/ABI 310 Genetic 
Analyzer
0.825BMC Blood Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2326/5/1
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the combination of three-color detection, multiple sets of
samples or multiple loci for a single sample can be ana-
lyzed on one gel. It is possible to analyze more than one
marker at a time after multiplex amplification of inform-
ative loci.
In the ALFExpress DNA Analyzer, electrophoresis is car-
ried out in an off-vertical gel cassette specially designed for
easy and safe gel casting. The number of samples to be
loaded on a gel is limited to 40 per run. The ALFwin Frag-
ment Analyzer is used afterwards for fragment analysis. It
is provided with versatile application software for the con-
trol of DNA fragment separation runs and subsequent
analysis of the data. Collected data are used to accurately
size PCR product peaks on the basis of external and inter-
nal standards.
One analysis of 40 samples takes 7 hrs, including PCR,
electrophoresis in the gel cassette, and paperwork. The
appropriate assembling and cleaning of the gel cassette is
critical and time consuming.
It is well known that FISH is a good quantitative method
of fluorescent signal detection, but requires lots of techni-
cal experience and expertise. Fluorescent in situ hybridiza-
tion for one patient sample lasts at least 5 hrs, including
preparation of interphase nuclei, hybridization with spe-
cific probes (X, Y dual-color FISH), and analysis. The high
cost of the procedure is definitely a disadvantage.
Discussion
PCR-based techniques allow the relative proportions of
recipient's and donor's cells in the post-HSCT period to be
identified and quantified and is not only limited to sex-
mismatched transplants. Although when using chimerism
analysis one cannot assess whether or not the population
of recipient's nucleated cells contains leukemic cells, sam-
ples taken at various intervals can show if the expansion
rate of the particular population is consistent with hema-
tologic and clinical symptoms of the disease. When it is
not possible to find an informative marker for PCR ampli-
fication, only FISH analysis enables assessing the chimer-
ism status. However, cytogenetic Y chromosome probing
by FISH is limited exclusively to sex-mismatched trans-
plantations. Results obtained with the use of ALFExpress
DNA Sequencer and ABI 310 Genetic Analyzer are identi-
cal or very similar. We showed that appropriate quantita-
tive assessment of chimerism after HSCT by using
microsatellite genotyping and automated DNA sizing
does not depend on the sequencer model used. The high
correlation between results from the PCR/ALFExpress and
PCR/ABI 310 Genetic Analyzer indicate that these two
methods can be used interchangeably. The superiority of
the ABI 310 Genetic Analyzer is limited to the possibility
of analysis of three samples at the same time in one reac-
tion tube and the technical ease of capillary electrophore-
sis with no need for the time-consuming and
cumbersome use of glass plates. Lower, but still positive
correlations were found between results of FISH analysis
and these two methodological variants of PCR. However,
in some samples analyzed with PCR, no recipient's signals
were found, attesting to full donor chimerism, while at the
same time residual host cells turned out to be detectable
by FISH. We suggest that these results are within the range
of error of the method applied.
Conclusions
Finally, we conclude that all the methods applied enable
a rapid and accurate detection of post-HSCT chimerism
and with due caution can be used interchangeably.
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